Literature DB >> 16885247

Oral anticoagulation in a pediatric hospital: impact of a quality improvement initiative on warfarin management strategies.

B S Moffett1, A L Parham, C D Caudilla, A R Mott, K D Gurwitch.   

Abstract

BACKGROUND: There are potential risks associated with the use of warfarin in children, particularly as the dosing requirements may decrease as patients get older. CONTEXT: Our facility is a 715-bed freestanding pediatric tertiary care center with a large cardiac surgery center. A significant number of patients receive warfarin for treatment or prophylaxis of thromboembolic events while in hospital. KEY MEASURES FOR IMPROVEMENT: Initial dose of warfarin and time taken to achieve goal therapeutic international normalized ratio (INR). STRATEGIES FOR CHANGE: The intervention included: (1) revision of hospital drug formulary so that warfarin dosing was in accordance with the most recent guidelines; (2) warfarin administration restricted to one time of the day (12.00 noon); (3) target therapeutic INR level documented with each warfarin order; and (4) pharmacy computer system mandated that the pharmacist confirmed the target INR, documented the most current INR, and compared the dose with the formulary guidelines. If the warfarin dose was not in accordance with the formulary guidelines, the pharmacist contacted the physician and made dosing recommendations according to the guidelines. EFFECTS OF CHANGE: The number of patients with supratherapeutic INR values during the hospital admission was decreased by more than 50% and goal INR values were documented more frequently in the medical record. There was also an increase in subtherapeutic INR values. The intervention had no effect on the time taken to achieve the goal therapeutic INR. LESSONS LEARNED: Instituting changes in a number of aspects of anticoagulation management and incorporating an intensive educational effort across a breadth of healthcare providers can improve anticoagulation management with warfarin in challenging patient populations such as children. Similar methods could possibly improve anticoagulation with other agents such as unfractionated heparin or low molecular weight heparin.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16885247      PMCID: PMC2564007          DOI: 10.1136/qshc.2005.014795

Source DB:  PubMed          Journal:  Qual Saf Health Care        ISSN: 1475-3898


  17 in total

1.  Medication errors: experience of the United States Pharmacopeia (USP) MEDMARX reporting system.

Authors:  John P Santell; Rodney W Hicks; Judy McMeekin; Diane D Cousins
Journal:  J Clin Pharmacol       Date:  2003-07       Impact factor: 3.126

Review 2.  Congenital heart disease in adults. A new cardiovascular subspecialty.

Authors:  J K Perloff
Journal:  Circulation       Date:  1991-11       Impact factor: 29.690

3.  Prosthetic replacement of the mitral valve. Continuing assessments of the 100 patients operated upon during 1961-1965.

Authors:  F H Levine; J G Copeland
Journal:  Circulation       Date:  1973-03       Impact factor: 29.690

4.  The changing state of surgery for adult congenital heart disease.

Authors:  J Monro
Journal:  Heart       Date:  2005-02       Impact factor: 5.994

5.  Warfarin therapy in children who require long-term total parenteral nutrition.

Authors:  Fiona Newall; Chris Barnes; Helen Savoia; Janine Campbell; Paul Monagle
Journal:  Pediatrics       Date:  2003-11       Impact factor: 7.124

6.  Thromboembolic complications after Fontan procedures: comparison of different therapeutic approaches.

Authors:  Ralf G Seipelt; Andreas Franke; Jaime F Vazquez-Jimenez; Peter Hanrath; Goetz von Bernuth; Bruno J Messmer; Eberhard G Mühler
Journal:  Ann Thorac Surg       Date:  2002-08       Impact factor: 4.330

7.  Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs.

Authors:  E Chiquette; M G Amato; H I Bussey
Journal:  Arch Intern Med       Date:  1998 Aug 10-24

8.  Oral anticoagulation in paediatric patients: dose requirements and complications.

Authors:  R C Tait; E J Ladusans; M El-Metaal; R G Patel; A M Will
Journal:  Arch Dis Child       Date:  1996-03       Impact factor: 3.791

9.  Oral anticoagulation therapy in pediatric patients: a prospective study.

Authors:  M Andrew; V Marzinotto; L A Brooker; M Adams; J Ginsberg; R Freedom; W Williams
Journal:  Thromb Haemost       Date:  1994-03       Impact factor: 5.249

10.  A retrospective evaluation of the management of excessive anticoagulation in an established clinical pharmacy anticoagulation service compared to traditional care.

Authors:  Daniel M Witt; Tammy L Humphries
Journal:  J Thromb Thrombolysis       Date:  2003-04       Impact factor: 2.300

View more
  1 in total

1.  Time in therapeutic range as a marker for thrombotic and bleeding outcomes in Fontan patients.

Authors:  Jenna M Faircloth; Kristin M Miner; Tarek Alsaied; Nicole Nelson; Julie Ciambarella; Tomoyuki Mizuno; Joseph S Palumbo; Alexander A Vinks; Gruschen R Veldtman
Journal:  J Thromb Thrombolysis       Date:  2017-07       Impact factor: 2.300

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.